Plain-English translation of NCT06675136 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing PIPAC, a new way to deliver chemotherapy medication directly into the abdomen during a minimally invasive procedure, combined with two standard intravenous cancer drugs ( and ). The study aims to find the safest and most effective dose of this combination treatment for people with advanced stomach cancer that has spread to the lining of the abdomen.
Stomach cancer that spreads to the abdominal lining is very difficult to treat with standard chemotherapy alone because the medication doesn't always reach the cancer effectively in that area. This trial is exploring whether delivering medication directly into the abdomen through a special aerosolized technique, combined with standard intravenous drugs, may work better and offer patients a new treatment option.
You likely qualify if…
You likely don't qualify if…
You would receive treatment in cycles over approximately 3–6 months. Every 8 weeks, you would undergo a minimally invasive abdominal procedure to receive the new medication directly into your abdomen, followed by intravenous infusions of the standard drugs given on specific days. Between treatments, you would have regular clinic visits for blood tests, imaging scans (CT or MRI), and biopsies to monitor how you're responding. You would also complete questionnaires about your quality of life and symptoms at various time points throughout the study.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States